3个月异源与同源增强接种灭活COVID-19疫苗与6个月同源增强接种BNT162b2的比较评估
这项基于马来西亚全国数据的回顾性队列研究纳入13 840 240名≥18岁完成CoronaVac或BNT162b2基础免疫且符合加强条件者,比较不同加强策略与BNT162b2基础免疫(2剂)参照组的有症状SARS-CoV-2感染 odds。以BNT162b2基础免疫为参照,CoronaVac基础+BNT162b2加强、3剂CoronaVac、3剂BNT162b2的有症状感染调整OR分别为0.06、0.08、0.01。≥60岁人群中,异源加强(CoronaVac基础+BNT162b2加强)较同源加强(3剂CoronaVac)感染 odds 更低(aOR 0.17 vs 0.19)。作者认为CoronaVac基础者3个月时用BNT162b2或CoronaVac加强的感染 odds 与BNT162b2基础者6个月时用BNT162b2加强相似,并建议≥60岁CoronaVac基础者异源加强。
要点
- 以BNT162b2基础免疫(2剂)为参照,3剂BNT162b2的有症状SARS-CoV-2感染aOR为0.01(95%CI 0.00-0.01)。
- CoronaVac基础+BNT162b2加强的有症状感染aOR为0.06(95%CI 0.05-0.06),3剂CoronaVac为0.08(95%CI 0.06-0.10)。
- ≥60岁人群,异源加强(CoronaVac基础+BNT162b2加强)较同源加强(3剂CoronaVac)感染 odds 更低(aOR 0.17 [95%CI 0.17-0.18] vs 0.19 [95%CI 0.19-0.20])。
- 作者认为CoronaVac基础者3个月时用BNT162b2或CoronaVac加强,有症状感染 odds 与BNT162b2基础者6个月时用BNT162b2加强相似。
- 作者建议≥60岁完成CoronaVac基础免疫者采用异源加强,因BNT162b2加强后观察到有症状感染 odds 更低。
适用人群与场景
- 马来西亚全国≥18岁、完成CoronaVac或BNT162b2基础免疫(2剂)且在2021年11月21日至2021年12月28日期间符合加强接种条件者。
处置流程与药物剂量
- 加强接种后≥14天视为完全加强,所有结局从该日起观察。
- 暴露分组:BNT162b2基础免疫(2剂)、CoronaVac基础免疫(2剂)、3剂BNT162b2、CoronaVac基础+BNT162b2加强、3剂CoronaVac。
研究设计与关键结果
- 研究类型:基于马来西亚全国数据的回顾性队列研究;样本量13 840 240人(平均[SD]年龄39.9[15.5]岁;7 040 298[50.9%]男性;4 451 180[32.2%]有≥1种合并症),其中5 081 641人(36.7%)已接种加强剂。
- 主要终点为有症状SARS-CoV-2感染;以BNT162b2基础免疫(2剂)为参照,CoronaVac基础+BNT162b2加强aOR 0.06(95%CI 0.05-0.06),3剂CoronaVac aOR 0.08(95%CI 0.06-0.10),3剂BNT162b2 aOR 0.01(95%CI 0.00-0.01)。
- ≥60岁人群中,异源加强(CoronaVac基础+BNT162b2加强)较同源加强(3剂CoronaVac)有症状SARS-CoV-2感染 odds 更低:aOR 0.17(95%CI 0.17-0.18)vs aOR 0.19(95%CI 0.19-0.20)。
- 次要终点为COVID-19相关ICU入住和死亡,摘要未报告具体结果数值。
证据类型、等级与局限
- 证据类型:基于全国数据的回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,完成CoronaVac基础免疫者在3个月时接种BNT162b2或CoronaVac加强,有症状SARS-CoV-2感染 odds 与完成BNT162b2基础免疫者在6个月时接种第3剂BNT162b2相似。
- 作者建议≥60岁完成CoronaVac基础免疫者采用异源加强(BNT162b2),因该人群异源加强后有症状SARS-CoV-2感染 odds 更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Evidence for the timing of booster vaccination after completion of BNT162b2 and CoronaVac primary vaccination is crucial to guide policy recommendations.
OBJECTIVE: To compare the odds of symptomatic SARS-CoV-2 infection and COVID-19-related outcomes after heterologous and homologous boosting of CoronaVac at 3-month intervals and homologous boosting of BNT162b2 at 6-month intervals, with BNT162b2 primary series (2 doses) as the reference group.
DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study used national data for Malaysia. Participants included all individuals aged 18 years and older who received a complete primary series of CoronaVac or BNT162b2 vaccine and were eligible for a booster dose between November 21, 2021, and December 28, 2021. Data were analyzed from November 21, 2021, to January 7, 2022.
EXPOSURES: Receipt of a booster vs no booster and categorized into primary series BNT162b2 (2 doses of BNT162b2), primary series CoronaVac (2 doses of CoronaVac), 3 doses of BNT162b2, primary series CoronaVac plus a BNT162b2 booster, and 3 doses of CoronaVac.
MAIN OUTCOMES AND MEASURES: The primary outcome was symptomatic SARS-CoV-2 infection. The secondary outcomes were COVID-19-related intensive care unit admission and death. All outcomes were observed from the day an individual was considered fully boosted (≥14 days after booster dose).
RESULTS: Our cohort included 13 840 240 individuals (mean [SD] age, 39.9 [15.5] years; 7 040 298 [50.9%] men; 4 451 180 individuals [32.2%] with ≥1 comorbidities), of whom 5 081 641 individuals (36.7%) had received a booster dose. Using the primary series BNT162b2 recipients as reference, the adjusted odds against symptomatic SAR-CoV-2 infection were lower for individuals who received the primary series CoronaVac plus a BNT162b2 (adjusted odds ratio [aOR], 0.06 [95% CI, 0.05-0.06]), 3 doses of CoronaVac (aOR, 0.08 [95% CI, 0.06-0.10]), or 3 doses of BNT162b2 (aOR, 0.01 [95% CI, 0.00-0.01]). Receipt of heterologous booster (primary series of CoronaVac plus a BNT162b2 booster) was associated with lower odds of SARS-CoV-2 infection (aOR, 0.17 [95% CI, 0.17-0.18]) compared with homologous booster (3 doses of CoronaVac) for individuals aged 60 years and older (aOR, 0.19 [95% CI, 0.19-0.20]).
CONCLUSIONS AND RELEVANCE: In this cohort study, for individuals who received the CoronaVac primary series and a booster dose of BNT162b2 or CoronaVac at 3 months, the observed odds of symptomatic SARS-CoV-2 infection were similar to individuals who received the BNT162b2 primary series plus a third dose of BNT162b2 at 6 months. Heterologous booster is recommended for individuals aged 60 years or older who received the CoronaVac primary series, given the lower observed odds against symptomatic SARS-CoV-2 infection among those who received a BNT1612b2 booster.
参考来源
- Low EV, Tok PSK, Husin M, et al. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months. JAMA Netw Open. 2022. PMID: 35947381. doi:10.1001/jamanetworkopen.2022.26046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。